NuCana plc Presents NUC-7738 Data at AACR Meeting
Ticker: NCNA · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-data, drug-development, conference-presentation
TL;DR
NuCana plc presenting NUC-7738 preclinical data at AACR, could be big for cancer treatment.
AI Summary
On April 9, 2024, NuCana plc announced the presentation of two posters detailing NUC-7738 at the American Association for Cancer Research (AACR) Annual Meeting. The posters will cover the drug's mechanism of action and preclinical data, highlighting its potential in treating various cancers.
Why It Matters
This presentation of preclinical data for NUC-7738 at a major cancer research conference could signal potential advancements in cancer treatment and attract further investor interest.
Risk Assessment
Risk Level: medium — The filing is an update on research progress, which carries inherent risks associated with drug development and clinical trial outcomes.
Key Players & Entities
- NuCana plc (company) — Registrant
- NUC-7738 (drug) — Drug candidate being presented
- American Association for Cancer Research (AACR) Annual Meeting (event) — Conference where data is presented
- April 9, 2024 (date) — Date of press release
FAQ
What specific data is being presented for NUC-7738 at the AACR Annual Meeting?
The press release states that two posters will be presented, covering the mechanism of action and preclinical data of NUC-7738.
When was the press release announcing the AACR presentation issued?
The press release was issued on April 9, 2024.
What is the primary focus of the NUC-7738 data being presented?
The focus is on NUC-7738's mechanism of action and preclinical data.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
Where is NuCana plc's principal executive office located?
NuCana plc's principal executive office is located at 3 Lochside Way, Edinburgh, United Kingdom.
Filing Stats: 329 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-04-09 16:43:28
Filing Documents
- d800505d6k.htm (6-K) — 10KB
- d800505dex991.htm (EX-99.1) — 14KB
- 0001193125-24-090901.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Donald Munoz Name: Donald Munoz Title: Chief Financial Officer Date: April 9, 2024